All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 20, 2026

Official filing document

Bills named in this filing 2

HR 4818
Gas Pipeline Leak Detection and Repair Act of 2025
S 2407
Charting My Path for Future Success Act

Lobbying activity 7

Taxation/Internal Revenue Code

International and domestic tax issues. Implementation of PL 119-21.

Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies.

Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products; H.R. 4818/S. 2407 - Treat and Reduce Obesity Act of 2023, Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Defense

Issues related to pharmaceutical manufacturing and development.

Pharmacy

Drug importation, prescription drug safety, value and access.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.